However, the specific mechanism by which TFAP2C transcriptionally activates Yes-associated protein (YAP) to promote cisplatin resistance in bladder cancer has not been previously reported, highlighting an innovative area for future research. Here, TFAP2C is linked to urinary bladder carcinoma.